Publication Procedure
This folder contains all information outlining the EU-GEI publication procedure, ensuring transparency and security.
The publication procedure is coordinated by Bart Rutten and Karin Quanten. All documents can be sent to Bea Campforts (bea.campforts@maastrichtuniversity.nl)

Part A: Procedure for approval of synopses
- EB reviews within 7 calendar days (info provided via email)
- GA reviews within 7 calendar days (info provided via website)

Document: format Synopses (click here to download FORMAT)

Part B: Procedure for approval of publication of scientific papers/manuscripts
- EB and GA review manuscripts within 30 calender days (info provided via website)

Part C: Procedure regarding abstracts / presentations
- EB reviews within 7 calendar days (info provided via email)
- GA reviews within 7 calendar days (info provided via website)

Document: EU-GEI Publication and Authorship Rules (click here to download RULES)

PUBLICATIONS TO BE APPROVED:

synopses to be approved:

manuscripts: no new manuscripts available
abstracts: no new abstract available  

ALL APPROVED SYNOPSES:

S2.2: Variation in the incidence of Schizophrenia and other psychotic disorders across Europe: finding form the multi-center EU-GEI study

S2.3: Incidence of psychotic disorders among migrants in EU Countries

S2.4:Childhood Adversity and Psychosis: Prevalence, Main Effects and Variation by Site

S2.5: Prevalence and impact of adult life events on first episode psychosis: a multi-centre study

S2.6: Proportion of First episode psychosis attributable to cannabis use across Europe: differences in pattern of cannabis use and their impact on first episode psychosis

S2.7: Improving Detection of Harmful Cannabis Use

S2.8: Childhood Adversity and Psychosis: Synergistic Effects and Mediatiors

S2.9: Incidence of psychotic disorders across Europe: analyses of determinants at small-area level in the EU-GEI study

S2.10 Indiviaul level determinants of high rates of psychosis in urban areas and minority ethnic groups: Finding from the multi-centre EU-GEI study

S2.11: Migration History and incidence of psychotic disorders among migrants in Europe

S2.12: The course of cognitive decline in schizophrenia

S2.13: G x E Cannabis

S2.14: G x E Childhood Adversity

S2.15: Cannabis use and social cognition in patients with first episode of psychosis and their siblings

S2.16: Differences in lifetime patterns of psychostimulant use and their impact on the proportion of patients with first episode psychosis across Europe

S2.17: DIfferences in lifetime patterns of tobacco use between patients with first episode psychosis and controls in an European sample

S2.19: Trauma history and impairment on emotional recognition on schizophrenia

S2.20: Association between child abuse, cognitvie impairment, and school attainment in first episode of psychosis patients and population controls

S2.21: Cannabis, migration and first episode psychosis

S2.22: Pathways to care and access to mental health services of patients at the first episode of psychosis in Europe

S2.23: Analysis of schizotypy measures in EU-GEI

S2.24: Environmental and genetic risk factors associated with schizotypy

S2.25: Premorbid adjustment and cannabis use in first episode psychosis patients

S2.26: General health comorbidity in first-episode psychosis: are the psychosis accelerated aging phenotypes

S2.28 Exploring the interplay between genetic distance and sociocultural factors in understaning the increases riskof psychotic disorders in ethnic minority groups

S2.29 Social and cultural distance as an explanation of higher rates of psychotic disorders in minority groups

S2.30 Does impaired affective mentalizing mediate the relationship between parental abuse and clinical and functional outcome in psychotic disorder?

S2.31: Is the excess of psychosis in people of African origin in Europe due to people of such origin with a predisposition to bipolar disorder being more likely to present psychotic symptoms than white people?

S2.32 Does variation in the prevalence of minor psychotic symptoms in control populations across Europe have a non-genetic origin?

S2.33 Psychosis Polygenic Risk scores and social cognition in psychotic disorders

S2.34 Shared and non-shared genetic and environmental risks of non-affective and affective psychotic disorders

S2.35  Polygenic risk scores for major psychiatric disorders explain differences in patterns of clinical and subclinical psychosis dimensions among cannabis users: a case-control analyses

S2.36   AGE OF ONSET OF PSYCHOSIS: ROLE OF CANNABIS USE IN FIRST EPISODE PSYCHOSIS PATIENTS (FEP)

S2.37   Using the EWAS cannabis signature to investigate the biological mechanism of cannabis associated psychosis

S2.38 The EU-GEI genome-wide association study: the relationship between the genetic risk of schizophrenia, cognitive performance and schizophrenia symptoms

S2.39 Age of onset and premorbid adjustment: are different pattern of cannabis use related to the supposed entities of deficit- and non-deficit-syndrome? S2.40 Can Polygenic Risk Scores explain the differences in Premorbid Social and Academic Adjustment, and current Cognition between those Psychotic patients who use cannabis compared to those who don’t?

S2.41 A case-control analyses of the DNA Methylation signature of tobacco, alcohol and stimulant use and its role in shaping individual risk to psychotic disorders.

S2.42 Polygenic risk and adverse environmental factors in Affective Psychosis

S2.43The impact of psycho-social stress factors on measures of attenuated psychosis (schizotypy/psychotic like experiences)

S2.44 The influence of paternal age on dimensions of attenuated psychosis (psychotic experiences/ schizotypy) and on risk for psychosis

S2.45 Dimensions of attenuated psychosis (schizotypy/ psychotic experiences) by migrant status and ethnicity

S2.47/ 5.32  Obsessive-compulsive symptoms in first episode and at risk mental state of psychosis: associations with cognitive functioning

S2.48/ 5.33  Obsessive-compulsive symptoms in first episode and at risk mental state of psychosis: associations with symptoms of psychosis and depression

S2.49 Tobacco use of subjects with a first psychotic episode and the association with neurocognition

S4.1: Altered neural stress processing in migrants

S5.1: Personality disorder traits and symptoms in young adults at ultra-high risk for psychosis

S5.2: Basic self disturbance and aberrant salience in the ultra high risk for psychosis population

S5.3: Genetic and environmental factors moderating sensitivity to stress in daily life: an experience sampling study

S5.4: Gender differences in Neuropsychology and Psychopathology in ARMS subject

S5.5: Social withdrawal, daily life stressors and psychotic experiences in patients with an At Risk Mental State for developing a psychotic disorder

S5.7: Stress sensitivity and brain structure in the At-Risk mental state

S5.8: Structural abnormalities in the Neural circuitry of Emotion - a Prelude to Psychosis

S5.9: MRI Fellowship: Trajectory of Brain Structure and Function before and after the Onset of Psychosis: a Longitudinal Multicentre Study

S5.10: Structural MRI of Childhood Adversity in the At-Risk Mental State for Psychosis

S5.11: Impairment in neurocognition as predictors of transition of Psychosis

S5.12: Cortical thickness in the at risk mental state, a prospective multicenter study

S5.13: Regional Gray matter volume in individuals at ultra high risk of developing psychosis

S5.14: Prevalence of anti-neuronal surface antibodies in people at ultra high risk (UHR) for psychosis: clinical significance,infective and inflammatory correlates and associated neuroimaging alterations

S5.15: Impact of comorbid disorders on baseline presentations and longitudinal outcomes in subjects at high clinical risk for psychosis

S5.16: Micro- vs. Macro-level emotional experience in the At Risk Mental State: possible clues for individualized treatment

S5.17: Brief limited intermittent psychotic episode: is it really a risk state?

S5.19: Prospective associations between self-reported sleep, subtle psychotic experiences and the transition to first-onset psychosis in young people at ultra high risk (UHR)

S5.20: The differential effects of childhood trauma and bullying and affective mediatiors on clinical outcome in patients at ultrahigh risk of developing a first psychotic episode

S5.21/S2.27: Obsessive-Compulsive symptoms and psychosis: a network approach

S5.22: The association of polygenetic score and environmental risk score on brain structure in UHR

S5.23: Association between genetic variation in the oxytocin pathway and receptor genes and social behavior in subjects at high clinical risk for psychosis

S5.24: Inflammatory markers and transistion to psychosis

S5.25:Aberrant salience as predictors of outcome of individuals with at-risk mental state

S5.26   A comparative network analysis of a compiled UHR cohort using CAARMS scores.

S5.27  Pathways from speech illusions to psychotic symptoms in subjects at ultra-high risk for psychosis: combining an experimental paradigm of aberrant experiences with network analysis

S5.28 The association between childhood trauma and facial and emotion recognition in individuals at ultra high risk of psychosis

S5.29 Impact of childhood trauma on educational achievement in young people at clinical high risk of psychosis

S5.30 Brain structure correlates of urban upbringing in individuals in the early stages of psychosis.

S5.31 Effects of built/physical environment on the brain structure of young people at high risk of developing psychosis

S2.47/ 5.32  Obsessive-compulsive symptoms in first episode and at risk mental state of psychosis: associations with cognitive functioning

S2.48/ 5.33  Obsessive-compulsive symptoms in first episode and at risk mental state of psychosis: associations with symptoms of psychosis and depression

S5.34 Tobacco use of subjects at ultra high risk to develop a first psychotic episode and the association with neurocognition.

S6.1  Schizotypy as an intermediate factor and environmental exposures impacting on schizophrenia onset

S6.2  Emotion recognition, separation from parents and genetics in schizophrenia 

S6.6  The cumulative and synergistic effect of environmental risk factors combined with polygenic risk for psychotic disorder on psychosis expression.

S6.7  The cumulative and synergistic effect of environmental risk factors combined with familial risk on psychosis expression in a sibling-control analysis

S2.54 / S6.8 Suicidality among first episode psychosis compared to control subjects: findings from the international multisite incidence EU-GEI study.